Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment.
Maniati E, Berlato C, Gopinathan G, Heath O, Kotantaki P, Lakhani A, McDermott J, Pegrum C, Delaine-Smith RM, Pearce OMT, Hirani P, Joy JD, Szabova L, Perets R, Sansom OJ, Drapkin R, Bailey P, Balkwill FR. Maniati E, et al. Among authors: berlato c. Cell Rep. 2020 Jan 14;30(2):525-540.e7. doi: 10.1016/j.celrep.2019.12.034. Cell Rep. 2020. PMID: 31940494 Free PMC article.
TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer.
Lecker LSM, Berlato C, Maniati E, Delaine-Smith R, Pearce OMT, Heath O, Nichols SJ, Trevisan C, Novak M, McDermott J, Brenton JD, Cutillas PR, Rajeeve V, Hennino A, Drapkin R, Loessner D, Balkwill FR. Lecker LSM, et al. Among authors: berlato c. Cancer Res. 2021 Nov 15;81(22):5706-5719. doi: 10.1158/0008-5472.CAN-21-0536. Epub 2021 Sep 24. Cancer Res. 2021. PMID: 34561272 Free PMC article.
Immune Mechanisms of Resistance to Cediranib in Ovarian Cancer.
Gopinathan G, Berlato C, Lakhani A, Szabova L, Pegrum C, Pedrosa AR, Laforets F, Maniati E, Balkwill FR. Gopinathan G, et al. Among authors: berlato c. Mol Cancer Ther. 2022 Jun 1;21(6):1030-1043. doi: 10.1158/1535-7163.MCT-21-0689. Mol Cancer Ther. 2022. PMID: 35313341 Free PMC article.
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer.
Berlato C, Khan MN, Schioppa T, Thompson R, Maniati E, Montfort A, Jangani M, Canosa M, Kulbe H, Hagemann UB, Duncan AR, Fletcher L, Wilkinson RW, Powles T, Quezada SA, Balkwill FR. Berlato C, et al. J Clin Invest. 2017 Mar 1;127(3):801-813. doi: 10.1172/JCI82976. Epub 2017 Jan 30. J Clin Invest. 2017. PMID: 28134623 Free PMC article.
16 results